Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-resistant Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03704467
What this trial is testing

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 3
Very early researchLooking for participantsNCT06660511
What this trial is testing

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Who this might be right for
Ovarian Cancer Recurrent
Second Xiangya Hospital of Central South University 5
Testing effectiveness (Phase 2)Study completedNCT03268382
What this trial is testing

P53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Who this might be right for
High-grade Serous Ovarian Cancer
Aprea Therapeutics 36
Testing effectiveness (Phase 2)Study completedNCT00856791
What this trial is testing

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
Traws Pharma, Inc. 1
Early research (Phase 1)Active Not RecruitingNCT05691504
What this trial is testing

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube Carcinoma+8 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Ended earlyNCT03608618
What this trial is testing

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Who this might be right for
Peritoneal MesotheliomaFallopian Tube AdenocarcinomaAdenocarcinoma of the Ovary+1 more
MaxCyte, Inc. 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07741630
What this trial is testing

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
PROC
Peking University Third Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02364713
What this trial is testing

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+24 more
Mayo Clinic 17
Testing effectiveness (Phase 2)Ended earlyNCT03610490
What this trial is testing

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Who this might be right for
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)UnknownNCT04375956
What this trial is testing

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06600841
What this trial is testing

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)Immunotherapy
Fujian Cancer Hospital 37
Early research (Phase 1)Study completedNCT00059618
What this trial is testing

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT00081276
What this trial is testing

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial Cancer+1 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Study completedNCT02431559
What this trial is testing

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ludwig Institute for Cancer Research 53
Testing effectiveness (Phase 2)Study completedNCT03804866
What this trial is testing

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Who this might be right for
Ovarian Cancer
AGC Biologics S.p.A. 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314619
What this trial is testing

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University 30
Early research (Phase 1)Active Not RecruitingNCT05156892
What this trial is testing

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Who this might be right for
Ovarian Cancer
Anthony Joshua, FRACP 44
Testing effectiveness (Phase 2)UnknownNCT03699449
What this trial is testing

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
Yonsei University 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Next Page